Pfizer

Healthcare isn’t one-size-fits-all. That’s why we created PfizerForAll. In a recent article, Aamir Malik, our Chief U.S. Commercial Officer, explains how our new digital platform is a resource for people with #migraine, #COVID19, and #flu. He also shares the challenges faced by two women managing migraine and COVID-19 and the ways that PfizerForAll is showing up for people in times of need. Read here to learn how PfizerForAll can help you:

On November 20th, we join in observing Trans Day of Remembrance, a day dedicated to honoring the memory of transgender individuals whose lives were tragically lost due to anti-transgender violence. This day serves as a poignant reminder of the ongoing challenges faced by the transgender community and underscores the importance of our collective efforts to foster a safe and inclusive environment for all. To mark this day and Transgender Awareness Week, members of OPEN (Out Pfizer Employee Network) gathered to writer letters of support to those in the transgender community. Their heartfelt messages aim to provide encouragement and solidarity to individuals who often face significant challenges.

Congratulations to the team at Ultromics on receiving FDA Clearance for EchoGo Amyloidosis – their innovative AI tech to help improve earlier detection of both light chain and transthyretin cardiac amyloidosis from a single 4 chamber echo scan. Great to see innovation in action for this serious and underdiagnosed cause of heart failure.

Today I have the privilege of announcing that Dr. Chris Boshoff, MD, PhD, FMedSci has been appointed to lead our pipeline of potential new medicines and vaccines—work that is at the very heart of Pfizer's ability to change patients' lives. Effective January 1, 2025, Chris will become Pfizer’s new Chief Scientific Officer and President, Research & Development, overseeing all functions of Pfizer’s R&D across all therapeutic areas.   In his current role as our Chief Oncology Officer, Chris has shaped Pfizer Oncology into one of our most productive divisions. In his 11 years at Pfizer, he has delivered an impressive 24 approved innovative medicines and biosimilars in more than 30 indications, and I am confident that he will accomplish great things across our entire portfolio. He is an extraordinary scientist and leader with a passion for helping patients. Throughout our comprehensive selection process, Chris stood out as a proven leader with a compelling vision for the future of Pfizer R&D.   Chris will succeed Dr. Mikael Dolsten, who is retiring at the end of the year. I want to thank Mikael for his dedication and all that he has contributed during his long tenure at Pfizer.   I’m also thrilled to announce Dr. Roger Dansey will serve as Interim Chief Oncology Officer and to welcome Dr. Johanna Bendell to Pfizer as our new Chief Development Officer, Oncology. Roger will work with Chris in selecting a permanent candidate for the role.   I look forward to working with these talented leaders and their teams to continue advancing scientific breakthroughs that help patients everywhere.   https://lnkd.in/eXT2ekYa

Is the Medicine in Your Medicine Cabinet Safe? Unfortunately, there is a troubling lack of knowledge about counterfeits among U.S. healthcare providers. Therein lies opportunity in empowering health care providers and patients

Understanding proteins helps unlock new insights, develop innovative treatments, and drive scientific progress. To introduce our new #explainer series, which breaks down some of the scientific concepts central to our work at Pfizer, we’re exploring what proteins are and how they play a vital role in countless daily processes within our bodies. #Proteins #Innovation

Pfizer has been recognized in the top 25% of Forbes' inaugural list of America's Best Employers for Tech Workers, where we are one of just four companies spotlighted in the Drug and Biotechnology category. Pfizer’s inclusion on this prestigious list is a testament to our dynamic and supportive culture, where every colleague has the opportunity to grow, excel, and make a meaningful impact. https://lnkd.in/gjmBJCbd

We’re supporting The Leukemia & Lymphoma Society as they work to define #BloodCancer and redefine what’s possible after diagnosis. Together, in partnership with the blood cancer community, we remain dedicated to making meaningful change to create a world where people with blood cancer live longer and better lives.

Today in a late-breaking presentation at ESMO - European Society for Medical Oncology 2024, we unveil new Phase 2 data in cancer cachexia, a life-threatening wasting condition with no FDA-approved treatments. Learn more about our #cachexia research: https://lnkd.in/eNS2kcB3 #Cachexia #ESMO24 

We’re pleased to partner with the International Myeloma Foundation to raise awareness of the impact of #MultipleMyeloma. Our long-standing relationships with the community are imperative in understanding and supporting the unique needs of patients as we work to deliver breakthroughs in #BloodCancer and #kNOwMyeloma.